BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1474165)

  • 1. Disposition of cefpodoxime proxetil in hemodialysis patients.
    Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    J Clin Pharmacol; 1992 Nov; 32(11):1038-44. PubMed ID: 1474165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis.
    Höffler D; Koeppe P; Corcilius M; Przyklinik A
    Infection; 1990; 18(3):157-62. PubMed ID: 2365467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
    St Peter JV; Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    Antimicrob Agents Chemother; 1992 Jan; 36(1):126-31. PubMed ID: 1590677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
    Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefpodoxime proxetil in healthy young and elderly volunteers.
    Borin MT; Ferry JJ; Forbes KK; Hughes GS
    J Clin Pharmacol; 1994 Jul; 34(7):774-81. PubMed ID: 7929873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the pharmacokinetics of cefpodoxime proxetil.
    Borin MT
    Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.
    Gehanno P; Andrews JM; Ichou F; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():47-51. PubMed ID: 2292530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.
    Tremblay D; Dupront A; Ho C; Coussediere D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():21-8. PubMed ID: 2292526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
    Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
    J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.
    Couraud L; Andrews JM; Lecoeur H; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():35-40. PubMed ID: 2292528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.
    Dumont R; Guetat F; Andrews JM; Sultan E; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():41-6. PubMed ID: 2292529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
    Borin MT; Hughes GS; Spillers CR; Patel RK
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1094-9. PubMed ID: 2393268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
    Saathoff N; Lode H; Neider K; Depperman KM; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1992 Apr; 36(4):796-800. PubMed ID: 1354432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food on absorption of cefpodoxime proxetil oral suspension in adults.
    Borin MT; Forbes KK
    Antimicrob Agents Chemother; 1995 Jan; 39(1):273-5. PubMed ID: 7695323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.
    Kumar V; Madabushi R; Lucchesi MB; Derendorf H
    J Vet Pharmacol Ther; 2011 Apr; 34(2):130-5. PubMed ID: 21395603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses.
    Carrillo NA; Giguère S; Gronwall RR; Brown MP; Merritt KA; O'Kelley JJ
    Am J Vet Res; 2005 Jan; 66(1):30-5. PubMed ID: 15691032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
    Kees F; Wellenhofer M; Bröhl K; Grobecker H
    Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
    Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
    J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.
    Muller-Serieys C; Bancal C; Dombret MC; Soler P; Murciano G; Aubier M; Bergogne-Berezin E
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2099-103. PubMed ID: 1444291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of timing of food on absorption of cefpodoxime proxetil.
    Borin MT; Driver MR; Forbes KK
    J Clin Pharmacol; 1995 May; 35(5):505-9. PubMed ID: 7657851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.